Searchable abstracts of presentations at key conferences in endocrinology

ea0041ep351 | Clinical case reports - Thyroid/Others | ECE2016

Saint John’s wort not so saint

Leon Claudia Arnas , Suarez Ana Delia Santana , Arroyo Sara Quintana , Calero Carmen Acosta , Martin Francisco Javier Martinez

Introduction: In addition to the medication prescribed by their doctors, patients may recourse to natural medicine and take herbal medications without thinking about their potential side effects and interactions with other drugs.Case Report: A 39-year-old female, with personal history of iron deficiency anemia, regular menses but long-standing dysmenorrhea and polymenorrhea and reactive anxiety-depressive disorder, complained of frequent intermenstrual s...

ea0090p533 | Late-Breaking | ECE2023

St. John’s wort as an example of the naturalistic fallacy: natural things are not necessarily good things

Rios-Gomez Carlos , Hernandez-Lazaro Alba , Jose de Leon-Durango Ricardo , Santana-Ojeda Borja , Arnas-Leon Claudia , Kuzior Agnieszka , Acosta-Calero Carmen , del Pino Ortiz-Hernandez Catherine , Maria Perez-Rivero Jennifer , Javier Martinez Martin Francisco

Introduction/Aim: New oral anticoagulant drugs such as the factor Xa inhibitor rivaroxaban are often preferred to the classic coumarins because they do not need frequent blood-test monitoring and have fever interactions with other drugs and foodstuffs. They are not, however, interaction free. Rivaroxaban is metabolized by oxidative degradation catalyzed by CYP3A4/5 and CYP2J2; it is also a substrate of the P-gp and ABCG2 efflux transporter proteins. CYP3A4 activity enhancers s...

ea0059mte10.1 | Service Improvements | SFEBES2018

GIRFT (Getting It Right First Time) for Endocrinology, NHS England John A. H. Wass, Professor of Endocrinology, University of Oxford and Department of Endocrinology, Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, Oxford OX3 7LJ, United Kingdom

Wass John

The GIRFT (Getting It Right First Time) visits, about which we have consulted the membership of the Society for Endocrinology and had positive feedback from many members, have now started. We have done four pilots in Birmingham, Leicester, Oxford and York. The objectives are to try to introduce a quantitative approach to help demonstrate best practice. It will explore surgical outcome data and complication rates with regard to thyroid, parathyroid, adrenal, pituitary and neuro...

ea0015s8biog | Clinical Endocrinology Trust Lecture | SFEBES2008

Clinical Endocrinology Trust Lecture

Connell John

John Connell, MRC Blood Pressure Group, Glasgow, UK AbstractJohn Connell graduated in medicine from Glasgow in 1977. After initial training in endocrinology, he was appointed as a Clinical Scientist to the MRC Blood Pressure Unit, Western infirmary, Glasgow in 1983. He held an MRC Travelling Fellowship in the Howard Florey Institute for Experimental Physiology and Medicine from 1987, working with Professor John Coghlan...

ea0025pl9biog | Clinical Endocrinology Trust Lecture | SFEBES2011

Clinical Endocrinology Trust Lecture

Bevan John S

John S Bevan, Department of Endocrinology, Aberdeen Royal Infirmary, Foresterhill, Aberdeen AB25 2ZN, UK. AbstractJohn S Bevan is senior Consultant Endocrinologist at Aberdeen Royal Infirmary and Honorary Professor of Endocrinology at Aberdeen University. He qualified MB ChB, with Honours, from Edinburgh University in 1978 and his clinical training in Medicine & Endocrinology took place in Edinburgh, Oxford and Ca...

ea0008p65 | Neuroendocrinology and behaviour | SFE2004

Characterization of formylated peptide receptor expression in murine brain, pituitary and adrenal tissue

Sahni V , John CD , Buckingham JC , Solito E

The formylated peptide receptors comprise a polymorphic family of seven transmembrane domain Gi-protein-coupled receptors. Three family members have been characterised in man (FPR, FPRL1 and FPRL2) and eight in mice (Fpr1, Fpr-rs1 to Fpr-rs7) (1). FPR was originally identified as a receptor for formylated bacterial peptides but recent studies suggest that it is also a target for annexin 1 (ANXA1) (2), a protein mediator of glucocorticoid action in the neuroendocrine system (3)...

ea0025p238 | Pituitary | SFEBES2011

Assessment of the feasibility of early hospital discharge following trans-sphenoidal pituitary surgery

Biswas Sujata , Barber Thomas , Cudlip Simon , Wass John

Objectives: Reducing length of inpatient stay following trans-sphenoidal pituitary adenectomy (TSA) could create significant financial saving for the NHS. We assessed early complication rates post-TSA to determine feasibility of early hospital discharge (3 days) post-TSA.Methods: We identified retrospectively 60 patients who underwent TSA at the John Radcliffe Hospital. These consisted of patients with a pre-operative confirmed diagnosis of non-functioni...

ea0008p69 | Neuroendocrinology and behaviour | SFE2004

Prolactin secretion in the male annexin 1 knockout mouse: effects of gonadectomy and testosterone replacement

Cover PO , Alexander A , McArthur SR , John CD , Morris JF , Christian HC , Buckingham JC

Prolactin secretion is sexually dimorphic and sensitive to changes in gonadal steroid and glucocorticoid status. Reports that the regulatory effects of glucocorticoids on prolactin release are mediated in part via annexin 1 (ANXA1, 1), have led us to compare prolactin secretion and lactotroph morphology in ANXA1 knockout (KO) and wildtype (WT) mice and to determine the effects gonadectomy +/- testosterone replacement (80 micrograms per day, s.c.) on (a) the plasma prolactin co...

ea0050cmw3.5 | Workshop 3: How do I. . . (1) | SFEBES2017

How do I . . . . investigate and manage a patient with Bartter or Gitleman syndrome?

Sayer John

Bartter and Gitelman syndromes are salt wasting alkaloses. These inherited conditions are the result of impairment of sodium chloride reabsorption in the loop of Henle (Bartter) or distal tubule (Gitelman). Secondary hyperaldosteronism occurs as a direct result of renal salt wasting resulting in hypokalaemia and metabolic alkalosis. The tubular defects seen mimic those of long-term loop (Bartter) or thiazide (Gitelman) diuretic use and urinary calcium levels and serum magnesiu...

ea0050cmw3.5 | Workshop 3: How do I. . . (1) | SFEBES2017

How do I . . . . investigate and manage a patient with Bartter or Gitleman syndrome?

Sayer John

Bartter and Gitelman syndromes are salt wasting alkaloses. These inherited conditions are the result of impairment of sodium chloride reabsorption in the loop of Henle (Bartter) or distal tubule (Gitelman). Secondary hyperaldosteronism occurs as a direct result of renal salt wasting resulting in hypokalaemia and metabolic alkalosis. The tubular defects seen mimic those of long-term loop (Bartter) or thiazide (Gitelman) diuretic use and urinary calcium levels and serum magnesiu...